Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG CLASS:

Purinergic receptor P1 agonist

DRUG CLASS:

Purinergic receptor P1 agonist

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Related drugs:

‹

cladribine (14)

cladribine (14)

›

No biomarker	Hairy Cell Leukemia	No biomarker	Hairy Cell Leukemia	cladribine Sensitive: A1 - Approval cladribine Sensitive : A1	cladribine Sensitive: A1 - Approval cladribine Sensitive : A1
No biomarker	Waldenstrom Macroglobulinemia	No biomarker	Waldenstrom Macroglobulinemia	cladribine Sensitive: A2 - Guideline cladribine Sensitive : A2	cladribine Sensitive: A2 - Guideline cladribine Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: A2 - Guideline cytarabine + cladribine Sensitive : A2	cytarabine + cladribine Sensitive: A2 - Guideline cytarabine + cladribine Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + idarubicin hydrochloride + cladribine Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + cladribine Sensitive : A2	cytarabine + idarubicin hydrochloride + cladribine Sensitive: A2 - Guideline cytarabine + idarubicin hydrochloride + cladribine Sensitive : A2
No biomarker	Acute Myelogenous Leukemia	No biomarker	Acute Myelogenous Leukemia	cytarabine + mitoxantrone + cladribine Sensitive: A2 - Guideline cytarabine + mitoxantrone + cladribine Sensitive : A2	cytarabine + mitoxantrone + cladribine Sensitive: A2 - Guideline cytarabine + mitoxantrone + cladribine Sensitive : A2
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
NPM1 mutation	Acute Myelogenous Leukemia	NPM1 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
FLT3 mutation	Acute Myelogenous Leukemia	FLT3 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
IDH2 mutation	Acute Myelogenous Leukemia	IDH2 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3	cytarabine + cladribine Sensitive: C3 – Early Trials cytarabine + cladribine Sensitive : C3
RUNX1 mutation	Acute Myelogenous Leukemia	RUNX1 mutation	Acute Myelogenous Leukemia	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3	decitabine + cladribine Sensitive: C3 – Early Trials decitabine + cladribine Sensitive : C3
TP53 mutation	Hairy Cell Leukemia	TP53 mutation	Hairy Cell Leukemia	rituximab + cladribine Resistant: C3 – Early Trials rituximab + cladribine Resistant : C3	rituximab + cladribine Resistant: C3 – Early Trials rituximab + cladribine Resistant : C3